{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:06:56Z","timestamp":1795064816878,"version":"4.10.2"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the effect of rituximab (RTX) on the lung function parameters in SSc interstitial lung disease (SSc-ILD) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed and Embase were searched to identify studies on SSc-ILD treated with RTX, confined to a predefined inclusion and exclusion criteria. A systematic review and meta-analysis were performed on the included studies on changes in forced vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO) from baseline to 6 and 12\u2009months of follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 20 studies (2 randomized controlled trials, 6 prospective studies, 5 retrospective studies and 7 conference abstracts) were included (n\u2009=\u2009575). RTX improved FVC from baseline by 4.49% (95% CI 0.25, 8.73) at 6\u2009months and by 7.03% (95% CI 4.37, 9.7) at 12\u2009months. Similarly, RTX improved DLCO by 3.47% (95% CI 0.99, 5.96) at 6\u2009months and 4.08% (95% CI 1.51, 6.65) at 12\u2009months. In the two studies comparing RTX with other immunosuppressants, improvement of FVC by 6\u2009months in the RTX group was 1.03% (95% CI 0.11, 1.94) greater than controls. At the 12\u2009month follow-up, RTX treatment was similar to controls in terms of both FVC and DLCO. Patients treated with RTX had a lower chance of developing infections compared with controls [odds ratio 0.256 (95% CI 0.104, 0.626), I2\u2009=\u20090%, P\u2009=\u20090.47).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment with RTX in SSc-ILD was associated with a significant improvement of both FVC and DLCO during the first year of treatment. RTX use was associated with lower infectious adverse events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa550","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T11:27:29Z","timestamp":1596194849000},"page":"557-567","source":"Crossref","is-referenced-by-count":97,"title":["Rituximab in the treatment of systemic sclerosis\u2013related interstitial lung disease: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8670-1745","authenticated-orcid":false,"given":"Rudra P","family":"Goswami","sequence":"first","affiliation":[{"name":"Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moumita","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, Aliah University, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, TATA Medical Center, Rajarhat, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8715-7726","authenticated-orcid":false,"given":"Geetabali","family":"Sircar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Post Graduate Medical Education and Research, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasar","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Post Graduate Medical Education and Research, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"2021020119052676200_keaa550-B1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021020119052676200_keaa550-B2","first-page":"215","article-title":"Efficacy and safety of rituximab in connective tissue disease related interstitial lung disease","volume":"32","author":"Fitzgerald","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2021020119052676200_keaa550-B3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.rdc.2014.12.005","article-title":"Interstitial lung disease in scleroderma","volume":"41","author":"Schoenfeld","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2021020119052676200_keaa550-B4","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021020119052676200_keaa550-B5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119052676200_keaa550-B6","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2021020119052676200_keaa550-B7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2021020119052676200_keaa550-B8","doi-asserted-by":"crossref","first-page":"190022","DOI":"10.1183\/16000617.0022-2019","article-title":"Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis","volume":"28","author":"Collins","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2021020119052676200_keaa550-B9","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford"},{"key":"2021020119052676200_keaa550-B10","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2021020119052676200_keaa550-B11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/BOR.0000000000000541","article-title":"Hematopoietic stem-cell transplantation in systemic sclerosis: an update","volume":"30","author":"Spierings","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2021020119052676200_keaa550-B12","first-page":"CD010908","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2021020119052676200_keaa550-B13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2021020119052676200_keaa550-B14","first-page":"581","article-title":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2021020119052676200_keaa550-B15","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021020119052676200_keaa550-B16","author":"Wells"},{"key":"2021020119052676200_keaa550-B17","author":"Higgins","year":"2011"},{"key":"2021020119052676200_keaa550-B18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"2021020119052676200_keaa550-B19","volume-title":"Statistical methods for meta-analysis","author":"Hedges","year":"1985"},{"key":"2021020119052676200_keaa550-B20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2021020119052676200_keaa550-B21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1037\/0033-2909.93.2.388","article-title":"A random effects model for effect sizes","volume":"93","author":"Hedges","year":"1983","journal-title":"Psychol Bull"},{"key":"2021020119052676200_keaa550-B22","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"2021020119052676200_keaa550-B23","first-page":"235","article-title":"Rituximab treatment for systemic sclerosis-associated interstitial lung disease","volume":"3","author":"Ananieva","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"2021020119052676200_keaa550-B24","first-page":"A648","article-title":"SAT0198 Rituximab for the treatment of systemic sclerosis associated interstitial lung disease: a case series","volume":"72","author":"Ananieva","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021020119052676200_keaa550-B25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2021020119052676200_keaa550-B26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.rbr.2016.04.001","article-title":"Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center","volume":"56","author":"Vilela","year":"2016","journal-title":"Rev Bras Reumatol"},{"key":"2021020119052676200_keaa550-B27","first-page":"832","article-title":"FRI0302 Safety and efficacy of rituximab biosimilar in systemic sclerosis: an Italian multicenter study","volume":"78","author":"Campochiaro","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021020119052676200_keaa550-B28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119052676200_keaa550-B29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021020119052676200_keaa550-B30","first-page":"ii100","article-title":"Application experience of rituximab in patients with SSc","volume":"51","author":"Desinova","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119052676200_keaa550-B31","first-page":"142","article-title":"Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study","volume":"36(Suppl 113","author":"Fraticelli","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2021020119052676200_keaa550-B32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/annrheumdis-2015-eular.4154","article-title":"FRI0484 Impact of anti-B-cell therapy with rituximab on pulmonary function of the patients with systemic sclerosis and interstitial lung disease","volume":"74","author":"Koneva","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021020119052676200_keaa550-B33","first-page":"86","article-title":"Rituximab efficacy in the patients with systemic scleroderma differing in extent of interstitial lung disease","volume":"3","author":"Koneva","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"2021020119052676200_keaa550-B34","first-page":"181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34(Suppl 100","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2021020119052676200_keaa550-B35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03009742.2013.869617","article-title":"Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen","volume":"43","author":"Moazedi-Fuerst","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2021020119052676200_keaa550-B36","article-title":"Efficacy of rituximab in systemic sclerosis with interstitial lung disease [abstract","volume":"68(Suppl 10","author":"Onat","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021020119052676200_keaa550-B37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/RHU.0000000000000584","article-title":"Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: a series of 14 patients","volume":"23","author":"Sari","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2021020119052676200_keaa550-B38","doi-asserted-by":"crossref","first-page":"102453","DOI":"10.1016\/j.autrev.2019.102453","article-title":"Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: a systematic review","volume":"19","author":"Bellan","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2021020119052676200_keaa550-B39","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejim.2013.02.008","article-title":"Using cyclophosphamide in inflammatory rheumatic diseases","volume":"24","author":"Brummaier","year":"2013","journal-title":"Eur J Intern Med"},{"key":"2021020119052676200_keaa550-B40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2021020119052676200_keaa550-B41","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI0215078","article-title":"CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse","volume":"109","author":"Saito","year":"2002","journal-title":"J Clin Invest"},{"key":"2021020119052676200_keaa550-B42","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021020119052676200_keaa550-B43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021020119052676200_keaa550-B44","doi-asserted-by":"crossref","first-page":"v65","DOI":"10.1093\/rheumatology\/ken313","article-title":"Pulmonary function tests","volume":"47(Suppl 5","author":"Behr","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119052676200_keaa550-B45","first-page":"1494","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension in a multi-center NIH clinical trial [abstract]","volume":"71(Suppl 10","author":"Nicolls","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021020119052676200_keaa550-B46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccm.2005.05.004","article-title":"Aging of the respiratory system: impact on pulmonary function tests and adaptation to exertion","volume":"26","author":"Janssens","year":"2005","journal-title":"Clin Chest Med"},{"key":"2021020119052676200_keaa550-B47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/oem.2004.018424","article-title":"The precision of longitudinal lung function measurements: monitoring and interpretation","volume":"62","author":"Hnizdo","year":"2005","journal-title":"Occup Environ Med"},{"key":"2021020119052676200_keaa550-B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.25039","article-title":"Good and bad memories following rituximab therapy","volume":"62","author":"St Clair","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/557\/36167871\/keaa550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/557\/36167871\/keaa550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T03:02:10Z","timestamp":1612321330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/2\/557\/5961492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,9]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa550","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,11,9]]}}}